Literature DB >> 25939273

Neuro-oncology: Primary CNS lymphoma treatment--the devil is in the details.

Lisa M DeAngelis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25939273     DOI： 10.1038/nrneurol.2015.64

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

1.  Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

Authors:  Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.

Authors:  Eckhard Thiel; Agnieszka Korfel; Peter Martus; Lothar Kanz; Frank Griesinger; Michael Rauch; Alexander Röth; Bernd Hertenstein; Theda von Toll; Thomas Hundsberger; Hans-Günther Mergenthaler; Malte Leithäuser; Tobias Birnbaum; Lars Fischer; Kristoph Jahnke; Ulrich Herrlinger; Ludwig Plasswilm; Thomas Nägele; Torsten Pietsch; Michael Bamberg; Michael Weller
Journal:  Lancet Oncol       Date:  2010-10-20       Impact factor: 41.316

3.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

4.  Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.

Authors:  Agnieszka Korfel; Eckhard Thiel; Peter Martus; Robert Möhle; Frank Griesinger; Michael Rauch; Alexander Röth; Bernd Hertenstein; Thomas Fischer; Thomas Hundsberger; Hans G Mergenthaler; Christian Junghanß; Tobias Birnbaum; Lars Fischer; Kristoph Jahnke; Ulrich Herrlinger; Patrick Roth; Michael Bamberg; Torsten Pietsch; Michael Weller
Journal:  Neurology       Date:  2015-02-25       Impact factor: 9.910

5.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

6.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Authors:  Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.

Authors:  Denise D Correa; Mary Rocco-Donovan; Lisa M DeAngelis; Rima Dolgoff-Kaspar; Fabio Iwamoto; Joachim Yahalom; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

8.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
  8 in total
  3 in total

1.  Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy.

Authors:  Prakash Ambady; Matthias Holdhoff; David Bonekamp; Fay Wong; Stuart A Grossman
Journal:  CNS Oncol       Date:  2015-10-28

2.  Whole Tumor Histogram-profiling of Diffusion-Weighted Magnetic Resonance Images Reflects Tumorbiological Features of Primary Central Nervous System Lymphoma.

Authors:  Stefan Schob; Benno Münch; Julia Dieckow; Ulf Quäschling; Karl-Titus Hoffmann; Cindy Richter; Nikita Garnov; Clara Frydrychowicz; Matthias Krause; Hans-Jonas Meyer; Alexey Surov
Journal:  Transl Oncol       Date:  2018-03-06       Impact factor: 4.243

3.  miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.

Authors:  Xinwei Li; Xueying Xu; Keng Chen; Haijian Wu; Yirong Wang; Shuxu Yang; Kun Wang
Journal:  Pathol Oncol Res       Date:  2019-02-02       Impact factor: 3.201
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.